D4 Labs, LLC announced today that it will present a paper entitled, “Immunogenicity and efficacy of a subcutaneously administered, adjuvanted vaccine containing modified S1 spike protein of SARS-CoV-2 variant C.1.2” at the fourth edition of the International Vaccines Congress in Baltimore, Maryland on October 24-26, 2024. The presentation deals with a new adjuvant system for vaccines called SubATVax™, which contains modified S1 spike protein sequences of the SARS-CoV-2 virus.
Dr. Wright, the Chief Scientific Officer at D4 Labs, LLC, stated:
“This is the first subcutaneously-administered, adjuvanted subunit spike protein vaccine for SARS-CoV-2 which generates IgG, IgA, and IgM responses with one dose of vaccine. A booster dose generates higher titered antibody responses, which last for over 120 days in our hamster model. This vaccine is administered through a 25 gauge needle.”
D4 Labs received a U.S. Patent (#11911461) for its subcutaneously administered adjuvant, SubATVax™, using modified S1 spike protein of SARS-CoV-2 variant C.1.2. A paper describing the preclinical testing of this technology was published in bioRxiv in September 2023.
For more information, please contact Dr. Wright (831) 664-5464